Logical Therapeutics Inc. Commences Double-Blind, Randomized Study Of Their Lead Program, LT-NS001

Logical Therapeutics, Inc.,
announced the commencement of its double-blind, randomized,
active-controlled, multinational study of LT-NS001, a novel prodrug, which
is converted in the bloodstream to naproxen, a non-steroidal
anti-inflammatory drug (NSAID). NSAIDs are the most common medications
taken worldwide for the treatment of pain, inflammation, fever and
arthritis, including both rheumatoid arthritis (RA) and osteoarthritis
(OA).



"Despite a long history of successfully treating patients for pain and
inflammation, NSAIDs have limitations that restrict their use.
Gastrointestinal (GI) side effects are a significant safety problem," said
Lutz Giebel, Chairman of Logical Therapeutics. Published studies have shown
that NSAID use is responsible for 15-60% of hospital admissions for GI
bleeding, amounting to approximately 100,000 hospitalizations and
10,000-20,000 deaths annually in the US. "A safer alternative would fulfill
a significant unmet medical need," Dr. Giebel went on to say.



In pre-clinical studies in rats and dogs, LT-NS001 was shown to cause
significantly less damage to the gastrointestinal tract than equivalent
doses of naproxen. The study will assess gastrointestinal injury by
endoscopy after 7 days of therapy. LT-NS001 was previously evaluated in two
Phase 1 randomized, placebo-controlled, single-dose and multiple-dose
pharmacokinetic studies. In all cases, LT-NS001 was well tolerated.
Moreover, when the subjects were dosed twice daily with LT-NS001, plasma
concentrations of naproxen were within the therapeutic range.



The Company also announced the departure of founding CEO, Dr. Mitchell
P. Fink, who resigned to pursue other interests.



About Logical Therapeutics Inc



Logical Therapeutics, Inc. is a privately held biotechnology company
based in Waltham, Massachusetts. Logical Therapeutics is developing drugs
to treat a variety of medical conditions that are associated with excessive
inflammation, including osteoarthritis and rheumatoid arthritis.


Logical Therapeutics, Inc

logicaltherapeutics